Skip to content

Minimal Residual Disease as a biomarker for postoperative recurrence monitoring in patients with biliary tumors

Correlation between ctDNA dynamic monitoring and postoperative recurrence or metastasis in patients with surgical biliary malignancy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068465
Enrollment
Unknown
Registered
2023-02-20
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract tumors

Interventions

Postoperative recurrence monitoring:Guidelines recommend postoperative standard adjuvant therapy

Sponsors

Hohhot First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with biliary malignant tumors that can undergo radical resection; (2) Refer to the UICC/AJCC TNM staging system (8th edition in 2017); (3) Agree to provide archived tumor tissue specimens or fresh tissue samples (which must have tissue specimens) and blood samples collected at different time nodes; (4) ECOG PS score 0-1; (5) The expected survival period is greater than 3 months; (6) Age 18-80 years old; (7) Willing to sign an informed consent form; (8) Patients can be followed up on schedule, can communicate well with the investigator and can complete the study in accordance with the research regulations.

Exclusion criteria

Exclusion criteria: (1) A patient with a previous malignancy shall not participate in the study unless he/she has complete remission for at least 5 years prior to enrolment and does not need to receive additional treatment or does not need to be admitted during the study Subject to other treatments (2) Combined severe medical diseases include, but are not limited to, uncontrolled diabetic active peptic ulcer active bleeding, etc (3) The method of sample collection and preservation is not standardized; (4) The relevant information of the subject is incomplete; (5) Patients who do not have enough communication, understanding and cooperation, or poor compliance, and cannot guarantee the completion of follow-up as required; (6) The investigator believes that the subject who is not suitable for participating in this clinical trial for various other reasons withdraws from the study or terminates the study treatment.

Design outcomes

Primary

MeasureTime frame
DFS;

Secondary

MeasureTime frame
routine blood test;urinalysis;

Countries

China

Contacts

Public ContactJunjing Zhang

Hohhot First Hospital

zhang.jj@vip.163.com+86 135 0069 6309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026